Multicell Technologies

Multicell Technologies Debt/EBITDA

The Total Debt to EBITDA Ratio of Multicell Technologies (MCET) as of Oct 11, 2026 is -0.12.

Debt/EBITDA

-0.12

Last updated:

Total Debt to EBITDA Ratio of Multicell Technologies is 2014 -0.12 . Total Debt to EBITDA Ratio of Multicell Technologies was 2013 - . It decreases by % lower compared to the previous year.

The Multicell Technologies Debt/EBITDA history

The Multicell Technologies Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.12—
Access this data via the Eulerpool API

Multicell Technologies Stock analysis

What does Multicell Technologies do? Multicell Technologies Inc is a US-American company specialized in the development and production of innovative products in the field of biomedical and biotechnological research. The company was founded in 1987 by a team of scientists and has held a leading position in the industry ever since. They develop technologies for the isolation and artificial reproduction of cell cultures, collaborate with leading scientists and research institutions to develop new methods and products for fighting diseases such as cancer and cardiovascular diseases, and offer a wide range of products for biomedical and biotechnological research, including cell culture systems, antibody products, and specialized analysis tools. They also work on the production of cell lines and cultures and develop active therapeutics, including a program for developing a new therapeutic for multiple sclerosis. Additionally, they have a diagnostics business and have developed a special platform for DNA sequencing. Overall, Multicell Technologies Inc is known for its close collaboration with the scientific community and its dedication to developing innovative products for the medical field. Multicell Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Multicell Technologies stock

Total Debt to EBITDA Ratio of Multicell Technologies is -0.12 in 2014.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Multicell Technologies since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Multicell Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Multicell Technologies

All Key Metrics — Multicell Technologies